Cargando…

Network meta-analysis of migraine disorder treatment by NSAIDs and triptans

BACKGROUND: Migraine is a neurological disorder resulting in large socioeconomic burden. This network meta-analysis (NMA) is designed to compare the relative efficacy and tolerability of non-steroidal anti-inflammatory agents (NSAIDs) and triptans. METHODS: We conducted systematic searches in databa...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Haiyang, Han, Wei, Wang, Jinghua, Li, Mingxian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5153398/
https://www.ncbi.nlm.nih.gov/pubmed/27957624
http://dx.doi.org/10.1186/s10194-016-0703-0
Descripción
Sumario:BACKGROUND: Migraine is a neurological disorder resulting in large socioeconomic burden. This network meta-analysis (NMA) is designed to compare the relative efficacy and tolerability of non-steroidal anti-inflammatory agents (NSAIDs) and triptans. METHODS: We conducted systematic searches in database PubMed and Embase. Treatment effectiveness was compared by synthesizing direct and indirect evidences using NMA. The surface under curve ranking area (SUCRA) was created to rank those interventions. RESULTS: Eletriptan and rizatriptan are superior to sumatriptan, zolmitriptan, almotriptan, ibuprofen and aspirin with respect to pain-relief. When analyzing 2 h-nausea-absence, rizatriptan has a better efficacy than sumatriptan, while other treatments indicate no distinctive difference compared with placebo. Furthermore, sumatriptan demonstrates a higher incidence of all-adverse-event compared with diclofenac-potassium, ibuprofen and almotriptan. CONCLUSION: This study suggests that eletriptan may be the most suitable therapy for migraine from a comprehensive point of view. In the meantime ibuprofen may also be a good choice for its excellent tolerability. Multi-component medication also attracts attention and may be a promising avenue for the next generation of migraine treatment. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s10194-016-0703-0) contains supplementary material, which is available to authorized users.